Melanoma Clinical Trial
IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)
Summary
Phase 3, multicenter, international, open-label, randomized, 2-arm trial investigating the safety and efficacy of IO102-IO103 in combination with pembrolizumab as first-line treatment for patients with previously untreated unresectable or metastatic (advanced) melanoma.
Patients will be stratified on the basis of the following factors; Disease stage: Unresectable stage IIID or stage IV M1a-b versus stage IV M1c-d and BRAFV600 mutation status: mutated vs wild type.
All patients will receive pembrolizumab 200 mg intravenously every 3 weeks for a maximum of 35 cycles corresponding to around 2 years of treatment. Patients randomized to IO102-IO103 dual-antigen, immunotherapeutic arm will also be given IO102-IO103 Q3W with an additional dose given during the induction period on Day 8 of cycles 1 and 2. IO102 IO103 will thereafter be administered subcutaneous every 3 weeks during the maintenance period. Each patient can be treated for a maximum of 37 administrations in total, corresponding to around 2 years of treatment.
The primary objective is to investigate the efficacy of IO102-IO103 in combination with pembrolizumab (compared with pembrolizumab alone) in terms of progression free survival.
Eligibility Criteria
Inclusion Criteria:
Histologically or cytologically confirmed stage III (unresectable) or stage IV melanoma, as per American Joint Committee on Cancer 8th edition guidelines not amenable to local therapy
Patients are treatment naive, that is, no previous systemic anticancer therapy for unresectable or metastatic melanoma. For clarification, the following patients are eligible:
Patients with BRAFV600 mutation-positive melanoma are eligible if treatment naive and without rapidly progressive disease as per investigators assessment. Documented BRAF V600 mutation status must be available from all patients prior to trial entry.
Patients who have received previous adjuvant and/or neoadjuvant therapy with targeted therapy or immune therapy are eligible if administered the last dose at least 6 months before inclusion in this trial (randomization), and if relapse did not occur during active treatment or within 6 months of treatment discontinuation.
At least 1 measurable lesion according to response evaluation criteria for solid tumors (RECIST v1.1) and confirmed by IRC.
Provision of archival (obtained within 3 months), or newly acquired biopsy tissue not previously irradiated, and blood at screening for biomarker assessments. Formalin-fixed, paraffin embedded (FFPE) tissue blocks are preferred to slides. Newly obtained biopsies are preferred to archived tissue.
Exclusion Criteria:
Patients with known or suspected central nervous system (CNS) metastases or with the CNS as the only site of active disease are excluded with the following exception:
• Patients with controlled (stable) brain metastases will be allowed to enroll (subject to baseline magnetic resonance imaging (MRI) confirmation). Controlled (stable) brain metastases are defined as those with no radiographic progression for at least 4 weeks after radiation and/or surgical treatment at the time of signed informed consent. Patients must have been off steroids for at least 2 weeks before signed informed consent and have no new or progressive neurological signs and symptoms.
Patient has received previous radiotherapy within 2 weeks of start of trial treatment (visit 2). Patients must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (≤2 weeks of radiotherapy) to non-CNS disease.
Patients with BRAFV600-positive disease who are experiencing rapidly progressing disease and/or have received standard first-line therapy with BRAF and/or MEK inhibitor for unresectable or metastatic disease.
Other protocol defined inclusion/exclusion criteria may apply.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 108 Locations for this study
Santa Monica California, 90404, United States
Orange City Florida, 32763, United States More Info
Principal Investigator
Orlando Florida, 32806, United States More Info
Principal Investigator
Lexington Kentucky, 40536, United States
Buffalo New York, 14221, United States More Info
Principal Investigator
Richmond Virginia, 23219, United States More Info
Principal Investigator
Albury New South Wales, 2640, Australia More Info
Principal Investigator
Westmead New South Wales, 2145, Australia More Info
Principal Investigator
Wollongong New South Wales, 2500, Australia More Info
Principal Investigator
Cairns Queensland, 4870, Australia More Info
Principal Investigator
Bedford Park South Australia, 5042, Australia More Info
Principal Investigator
Woodville South South Australia, 5011, Australia More Info
Principal Investigator
Birtinya , 4575, Australia More Info
Principal Investigator
Melbourne , 3052, Australia More Info
Principal Investigator
Gent Oost-Vlaanderen, 9000, Belgium More Info
Principal Investigator
Brugge , 8000, Belgium More Info
Principal Investigator
Hradec Králové , 500 0, Czechia More Info
Principal Investigator
Olomouc , 779 0, Czechia More Info
Principal Investigator
Praha , 10034, Czechia More Info
Principal Investigator
Aalborg , 9000, Denmark More Info
Principal Investigator
Aarhus , 8200, Denmark More Info
Principal Investigator
Herlev , 2730, Denmark More Info
Principal Investigator
Besancon , 25000, France More Info
Contact
Principal Investigator
Bordeaux , 33075, France More Info
Principal Investigator
Boulogne Billancourt , 92100, France More Info
Contact
Principal Investigator
Dijon , 21079, France More Info
Principal Investigator
La Tronche , 38700, France More Info
Principal Investigator
Lille , 59000, France More Info
Principal Investigator
Marseille cedex 05 , 13385, France More Info
Principal Investigator
Nice , 6200, France More Info
Principal Investigator
Pierre Benite , 69495, France More Info
Principal Investigator
Rennes Cedex , 35042, France More Info
Principal Investigator
Saint Herblain , 44805, France More Info
Principal Investigator
Valence , 26 95, France More Info
Principal Investigator
Villejuif Cedex , 94805, France More Info
Principal Investigator
Augsburg , 86179, Germany More Info
Principal Investigator
Berlin , 13353, Germany More Info
Principal Investigator
Bochum , 44791, Germany More Info
Principal Investigator
Erlangen , 90054, Germany More Info
Principal Investigator
Essen , 45147, Germany More Info
Principal Investigator
Frankfurt , 60590, Germany More Info
Principal Investigator
Heidelberg , 69120, Germany More Info
Principal Investigator
Heilbronn , 74078, Germany More Info
Principal Investigator
Kiel , 24105, Germany More Info
Principal Investigator
Mainz , 55131, Germany More Info
Principal Investigator
Mannheim , 68167, Germany More Info
Principal Investigator
Minden , 32429, Germany More Info
Contact
Principal Investigator
Wuerzburg , 97080, Germany More Info
Principal Investigator
Budapest , 1122, Hungary More Info
Principal Investigator
Pecs , 7632, Hungary More Info
Principal Investigator
Szolnok , 5000, Hungary More Info
Principal Investigator
Dublin , 7, Ireland
Beer Sheva , 84101, Israel More Info
Principal Investigator
Jerusalem , 91120, Israel More Info
Principal Investigator
Petah Tikva , 49414, Israel More Info
Principal Investigator
Tel Aviv-Yafo , , Israel More Info
Principal Investigator
Tel Hashomer , 52621, Israel More Info
Principal Investigator
Ancona , 60126, Italy More Info
Principal Investigator
Aviano , 33081, Italy More Info
Principal Investigator
Bari , 70124, Italy More Info
Principal Investigator
Candiolo , 10060, Italy More Info
Principal Investigator
Genova , 16132, Italy More Info
Principal Investigator
Meldola , 47014, Italy More Info
Principal Investigator
Milano , 20133, Italy More Info
Principal Investigator
Napoli , 80131, Italy More Info
Principal Investigator
Padova , 35128, Italy More Info
Principal Investigator
Perugia , 6156, Italy More Info
Principal Investigator
Siena , 53100, Italy More Info
Principal Investigator
Amsterdam , 1066, Netherlands More Info
Principal Investigator
Amsterdam , 1081, Netherlands More Info
Principal Investigator
Utrecht , 3584, Netherlands More Info
Principal Investigator
Warsaw Masovian, 02-78, Poland More Info
Principal Investigator
Poznan , 60-78, Poland More Info
Principal Investigator
Cape Town , 7570, South Africa More Info
Principal Investigator
Pretoria , 0181, South Africa More Info
Principal Investigator
Seville Andalusia, 41009, Spain More Info
Principal Investigator
A Coruña , 15006, Spain More Info
Principal Investigator
Barcelona , 08036, Spain More Info
Principal Investigator
Barcelona , 8028, Spain More Info
Principal Investigator
Barcelona , 8916, Spain More Info
Principal Investigator
Madrid , 28007, Spain More Info
Principal Investigator
Madrid , 28027, Spain More Info
Principal Investigator
Madrid , 28034, Spain More Info
Principal Investigator
Madrid , 28050, Spain More Info
Principal Investigator
Malaga , 29010, Spain More Info
Principal Investigator
Oviedo , 33011, Spain More Info
Principal Investigator
Pamplona , 31008, Spain More Info
Principal Investigator
Valencia , 46014, Spain More Info
Principal Investigator
Valencia , 46026, Spain More Info
Principal Investigator
Zaragoza , 50009, Spain More Info
Principal Investigator
Adana , 1060, Turkey More Info
Principal Investigator
Ankara , 6010, Turkey More Info
Principal Investigator
Antalya , 7059, Turkey More Info
Principal Investigator
Bornova , 35100, Turkey More Info
Principal Investigator
Istanbul , 34098, Turkey More Info
Principal Investigator
Istanbul , 34722, Turkey More Info
Principal Investigator
Manchester , M20 4, United Kingdom More Info
Principal Investigator
Manchester , M20 4, United Kingdom More Info
Principal Investigator
Oxford , OX3 7, United Kingdom More Info
Principal Investigator
How clear is this clinincal trial information?